Vanguard Group Inc. Has $49.63 Million Stock Holdings in Biohaven Ltd. $BHVN

Vanguard Group Inc. grew its position in shares of Biohaven Ltd. (NYSE:BHVN) by 52.9% during the fourth quarter, HoldingsChannel.com reports. The firm owned 4,395,946 shares of the company’s stock after purchasing an additional 1,520,756 shares during the period. Vanguard Group Inc.’s holdings in Biohaven were worth $49,630,000 at the end of the most recent quarter.

Several other institutional investors also recently modified their holdings of BHVN. Qube Research & Technologies Ltd grew its stake in shares of Biohaven by 834.4% in the third quarter. Qube Research & Technologies Ltd now owns 1,265,597 shares of the company’s stock worth $18,997,000 after purchasing an additional 1,130,157 shares during the last quarter. Two Sigma Investments LP boosted its position in Biohaven by 986.0% during the third quarter. Two Sigma Investments LP now owns 799,600 shares of the company’s stock valued at $12,002,000 after acquiring an additional 725,969 shares during the last quarter. Aberdeen Group plc bought a new stake in Biohaven during the fourth quarter valued at $7,829,000. Cubist Systematic Strategies LLC bought a new stake in Biohaven during the second quarter valued at $9,289,000. Finally, BNP Paribas Financial Markets boosted its position in Biohaven by 6,907.3% during the second quarter. BNP Paribas Financial Markets now owns 628,622 shares of the company’s stock valued at $8,870,000 after acquiring an additional 619,651 shares during the last quarter. Institutional investors own 88.78% of the company’s stock.

Biohaven Price Performance

Shares of NYSE BHVN opened at $8.74 on Friday. The firm’s 50-day moving average price is $9.57 and its 200-day moving average price is $10.65. Biohaven Ltd. has a 1-year low of $7.48 and a 1-year high of $18.57. The firm has a market capitalization of $1.32 billion, a P/E ratio of -1.54 and a beta of 1.32. The company has a current ratio of 7.41, a quick ratio of 7.41 and a debt-to-equity ratio of 1.87.

Biohaven (NYSE:BHVN) last announced its quarterly earnings data on Monday, May 4th. The company reported ($0.88) earnings per share for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Equities research analysts anticipate that Biohaven Ltd. will post -2.97 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have commented on BHVN shares. Canaccord Genuity Group started coverage on shares of Biohaven in a research report on Monday, April 13th. They set a “buy” rating and a $21.00 price target on the stock. TD Cowen upped their price target on shares of Biohaven from $15.00 to $30.00 and gave the company a “buy” rating in a research report on Wednesday, March 11th. The Goldman Sachs Group raised shares of Biohaven to a “strong-buy” rating in a research report on Friday, February 6th. Wall Street Zen lowered shares of Biohaven from a “sell” rating to a “strong sell” rating in a report on Sunday, April 26th. Finally, HC Wainwright dropped their price objective on shares of Biohaven from $11.00 to $10.00 and set a “neutral” rating on the stock in a report on Wednesday, March 4th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $22.27.

About Biohaven

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.